Senseye is building the breakthrough diagnostic platform for mental health, starting with PTSD. The company has developed an AI-driven technology that uses smartphone cameras to analyze ocular biomarkers, measuring disruptions in the sympathetic nervous system through the eyes. This non-invasive approach provides clinicians with fast, accurate tools for establishing clear baselines and tracking outcomes over time. The platform delivers sub-10-minute assessments without requiring internet connectivity or specialized equipment, making it ideal for telehealth and remote settings.
Senseye's clinically validated technology leverages computer vision and deep learning to extract signals from the autonomic nervous system via the eyes. The platform has been used by over 3,000 patients and is advancing toward FDA approval for PTSD and Major Depressive Disorder. With applications spanning clinical healthcare, pharmaceutical research, and military medicine, Senseye addresses the urgent need for objective mental health diagnostics. The company has raised over $30M in funding and received strategic investment from Topcon Healthcare, positioning its technology to revolutionize how mental health is diagnosed and monitored worldwide.
